MyMedR

Displaying all 2 publications

Abstract:

Sort:

Predictive markers of early endothelial dysregulation in type-1 diabetes: a meta-analysis

Ranasinghe R, Mathai M, Alshawsh MA, Zulli A, Ranasinghe R

Acta Diabetol, 2024 Nov 11.
PMID: 39527296 DOI: 10.1007/s00592-024-02401-2

BACKGROUND: This study identifies a new set of salient risk factors that may trigger danger signals of vascular dysregulation in T1D. Vascular abnormalities and impairment of CVD is a major adverse effect of T1D, particularly affecting children, adolescents and young adults.
METHODS: The patients of T1D were compared with the healthy control (HC) for the risk factors of vascular dysregulation in published studies from year 2013 to 2023. The PubMed, Web of Science and Google Scholar databases were searched from 1/1/2013 to 1/9/2023. The risk of bias was assessed with the Cochrane (ROBINS-I ) tool, relevant to clinical subjects. A random effects model was followed and analysed by RevMan 5.4 and GraphPad Prism software.
RESULTS: 80 relevant case-control studies having 7492 T1D patients and 5293 HC were included. The age and sex-matched HC consisted of persons free of disease and not under any medication while clinical subjects of
Fulltext Nanocarrier-mediated cancer therapy with cisplatin: A meta-analysis with a promising new paradigm

Ranasinghe R, Mathai M, Abdullah Alshawsh M, Zulli A

Heliyon, 2024 Apr 15;10(7):e28171.
PMID: 39839154 DOI: 10.1016/j.heliyon.2024.e28171

AIMS: Cisplatin is a frontline chemotherapeutic utilized to attenuate multiple cancers in the clinic. Given its side-effects, a new cisplatin formulation which could prevent cytotoxicity, metabolic deficiencies and metastasis is much needed. This study investigates whether nanocarriers can provide a better mode of drug delivery in preclinical cancer models seeking a potent anticancer therapeutic agent.
MATERIALS AND METHODS: The PubMed database was searched, and 242 research articles were screened from which 94 articles qualified for selection from those published by December 31, 2023 and the data was synthesized using the Review Manager software.
KEY FINDINGS: Cisplatin encapsulated as a nanomedicine confirmed the versatility of nanocarriers in significantly diminishing cancer cell viability, half maximal inhibitory concentration, tumour volume, biodistribution of platinum in tumours and kidney; at p

Filters

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links